New test predicts whether patients with blood cancer respond to therapy

January 15, 2018 by Wendy Van Zuijlen, University of New South Wales
New test predicts whether patients with blood cancer respond to therapy
Credit: Shutterstock

A new method developed by UNSW Sydney medical researchers offers a way to predict whether patients with the blood condition myelodysplastic syndrome will respond to treatment.

Myelodysplastic syndrome (MDS) is characterised by impaired peripheral blood cell production and abnormal , and more than 1400 people in Australia are diagnosed with the disease each year. MDS is much more common in older individuals and, if left untreated, the prognosis can be very poor.

Bone marrow transplantation could cure MDS. But this is an invasive procedure that is often not tolerated by older people. The best alternative is the drug azacitidine (AZA), which can improve blood production and decrease the likelihood of MDS progressing into leukemia.

"About half of MDS will not respond to AZA, with few alternatives for those who fail ," says UNSW Research Fellow Dr. Ashwin Unnikrishnan.

"Also, it takes about four to six months before we can tell if someone is responding to AZA treatment, at which point months of futile treatment has been given to those who are resistant to it."

To address this issue, UNSW Medicine researchers led by Dr. Unnikrishnan and Professor John Pimanda set out to develop a new quantitative method to measure AZA in patients receiving the treatment, to predict their response.

This method builds on their recent discovery that increased cell cycle quiescence of blood cells is a characteristic of patients who fail to respond to AZA treatment.

"The new method, called AZA-MS, utilises a cutting-edge technique known as mass spectrometry to measures the different forms of AZA inside of patients – such as the AZA molecules that are incorporated into the DNA or RNA," says Dr. Unnikrishnan.

New test predicts whether patients with blood cancer respond to therapy
Professor Pimanda and Dr Unnikrishnan. Credit: University of New South Wales

"This development was very much an interdisciplinary effort involving researchers in the stem cell laboratory at the Lowy Cancer Research Centre and mass spectrometry experts at the Mark Wainwright Analytical Centre," he says.

The team's discoveries using AZA-MS are published in the journal Leukemia and reveal that MDS patients who do not respond to AZA treatment incorporate less AZA molecules in their DNA, compared to people who do respond. These findings are consistent with the team's hypothesis that increased cell cycle quiescence of is a key driver of resistance to AZA treatment.

"These findings are really exciting, because AZA-MS now allows us to identify early on which patients will not respond to AZA," says Dr. Unnikrishnan.

In early 2018, the AZA-MS method, along with another related test, will be used in a UNSW clinical trial led by Professor Pimanda, together with the pharmaceutical company Celgene and multiple hospitals in New South Wales.

"One of the benefits of using the test in this trial is that it will help determine if people respond to AZA tablets, compared to the currently used injectable form," says Professor Pimanda.

Dr. Unnikrishnan says: "The hope is that the AZA tablets will be effective for people who would otherwise not respond to AZA, and that the overall response to AZA improves.

"The clinical trial will also allow us to collect samples that will enable us to answer long-term questions aimed at improving treatment in MDS.

"Altogether, we are hoping to fundamentally improve treatment for MDS patients, with the test as a big step towards personalised therapy," he says.

Explore further: Improving the 'wait and see' approach in MDS blood cancer treatment

Related Stories

Improving the 'wait and see' approach in MDS blood cancer treatment

July 18, 2017
Researchers are closer to helping the 50 per cent of people with a group of blood disorders that can transform into acute leukaemia, but who don't respond to the best available treatment.

Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

September 27, 2017
A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.

Scientists discover rogue messengers that hinder body's immune response to cancer

September 27, 2017
Researchers from Trinity College Dublin have made a discovery around treatment-resistant breast cancer that may turn the phrase, 'don't shoot the messenger', on its head. The scientists have found that cell to cell messengers ...

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Patient's immune status associated with outcome following third-generation CAR T-cell therapy

September 6, 2017
Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival was associated with the patient's immune status, according ...

Combination therapy shown as effective for higher-risk MDS/AML patients

December 8, 2014
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with ...

Recommended for you

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Tumor cells evade death through in extremis DNA repair

May 24, 2018
Greater knowledge of the mechanisms that contribute to the survival of tumour cells is key to vanquishing them. The study published today in the journal Cancer Cell, headed by Angel R. Nebreda, ICREA researcher at the Institute ...

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

Cancer cells co-opt pain-sensing 'wasabi receptor' to survive oxidative stress

May 24, 2018
Anyone who's taken a bite of a sandwich with too much spicy mustard or a piece of sushi with too much wasabi can attest to the tear-inducing sensation these condiments can cause. These loud warnings to the nervous system ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.